<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

Freddy Buntoum

18+ years’ experience with expertise in Market Insights and Competitive Intelligence at major manufacturers in Medical Device and Crop Science, including 4+ years at Bioventus as a Sr. Manager, Market Insights.

Recent Posts

2 min read

A Wild COVID Roller Coaster Ride: Q220 & Q320 Soft Tissue Fixation Market Recap

By Freddy Buntoum on 1/8/21 11:12 AM

Although the COVID-19 roller coaster was a tough ride in Q220, Soft Tissue Fixation was stepping out and looking good in Q320

When an unpredictable COVID-19 roller coaster hit the tracks, companies saw revenue plummet in Q220 as stay-at-home orders were implemented (mid-March) and elective surgeries were canceled or postponed indefinitely. The impact of COVID-19 that forced government-imposed restrictions was felt throughout the 2
Topics: Orthopedics
Continue Reading
2 min read

A Q320 Ray of Sunshine: US Joint Fluid Replacement Market Recap

By Freddy Buntoum on 1/7/21 10:00 AM

Q320 - The bright ray of sunshine companies had hoped for after dismal results in Q220

While Q220 is down in history as a disastrous quarter, marred by the dark mark of COVID-19, Q320 is the bright ray of sunshine companies in the US Joint Fluid Replacement market had hoped for.

For Q320, HA companies shared upbeat notes about renewed product demand, fueled by an uptick in activity from patients (out and about), distribution channels, and physicians treating an influx of new, as well as existing patients. One of the factors benefiting the HA market is the backlog of patients awaiting their turn for knee arthroplasty (TKA) and remain in need of treatment to manage their knee osteoarthritis (KOA) pain. 

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 US Joint Fluid Market Recap* are:

Continue Reading
9 min read

Current and Emerging Research in Orthopedic Regenerative Medicine

By Freddy Buntoum on 11/16/20 6:24 PM

The Regenerative Medicine market for orthopedic and sports medicine applications is rapidly advancing as clinicians increasingly look to novel injectable options to accelerate the healing of injured joints, tendons and/or other soft tissues. Several companies are conducting research into the use of PRP, BMA/BMC, amniotic tissue products, exosomes and other regenerative medicine therapies to treat degenerative and/or chronic conditions such as osteoarthritis (OA), degenerative disc/spine disease, chronic low back pain, tendinopathy and rotator cuff tears. This includes Arthrex, Emcyte, ISTO Biologics, MiMedx and Harvest/Terumo among others.

The following is a sampling of SmartTRAK market updates covering recently published studies, articles and clinical trials in orthopedic regenerative medicine that were compiled, reviewed and posted in real time by Freddy Buntoum, SmartTRAK’s Sr. Analyst, Regenerative Medicine and Sports Medicine.

Continue Reading
15 min read

Ideas, Concepts and Innovations: A Window into Soft Tissue Fixation

By Freddy Buntoum on 11/3/20 6:30 AM

In the Sports Medicine market, companies with soft tissue fixation products continue to innovate and pursue patents that provide a window into company ideas, concepts and future technologies. SmartTRAK takes a look at the top competitors in this space, including Arthrex, Smith & Nephew, DePuy Synthes, Zimmer Biomet, Stryker and CONMED Linvatec.

Freddy Buntoum, SmartTRAK’s Sr. Analyst, Regenerative Medicine and Sports Medicine, highlights recently granted patents and published patent applications in soft tissue fixation that describe novel methods, techniques, materials and devices for the repair and reconstruction of soft tissue injuries in the shoulder, extremities, hip and knee.

Arthrex*

Arthrex’s US Patent “Knotless tissue fixation assembly” was granted describing a tissue fixation device for securing soft tissue to bone with excellent pull-out strength without requiring suture knots to secure the suture in place or to secure the tissue to the bone. 10,716,556

Topics: Orthopedics
Continue Reading
2 min read

COVID Clobbers Companies: Q220 US Joint Fluid Replacement Market Recap

By Freddy Buntoum on 9/25/20 11:12 AM

Heavy-weight contender ​COVID-19 landed some brutal blows to revenue in Q220, but companies look for better days in the second half of 2020. 

The impact of the COVID-19 crisis started to hit the US Joint Fluid Replacement market late in Q120, and, to some degree, this helped to shield HA companies from heavy punches to revenue. Although none were left KO’d in round one, they still came through bruised up. Going into Q220 for round two, HA companies prepared as best as they could and braced for impact. Unfortunately, COVID-19 is a formidable opponent and even with strong cost-control measures in place, companies were hit hard with huge revenue losses for products in the three largest segments of the US Joint Fluid Replacement market.


Among the many topics covered in the comprehensive Q220 US Joint Fluid Replacement Market Recap* are:

Continue Reading
4 min read

Back Down the Revenue Track: Q120 Soft Tissue Fixation Market Recap

By Freddy Buntoum on 7/10/20 10:37 AM

A well-oiled engine, the Soft Tissue Fixation train was prepped for a good start to 2020, then COVID-19 sent it in reverse back down the revenue tracks.

Looking back at how 2019 finished, market sentiment was quite optimistic that 2020 could be another positive year for the WW Soft Tissue Fixation Market. With +3.7% YoY growth in Q419, the first quarter of 2020 seemed set for a good start, with companies chugging along nicely, actively pushing products, planning or recruiting for clinical trials, and some of them also receiving FDA 510(k) clearance for new products or for line extensions. All appeared to be business as usual, that is, until COVID-19 reared its ugly head, picking China as its first target. Alas, the rapid worldwide spread of this devastating virus forced a major halt in elective procedures to enable healthcare systems to focus on the rising number of COVID-19 cases. 

Among the many topics covered in the comprehensive Q120 Soft Tissue Fixation Market Recap* are:

Continue Reading
6 min read

Q120 US Joint Fluid Replacement Market: Riding Out the COVID-19 Storm

By Freddy Buntoum on 6/8/20 5:35 PM

Coming through Q120 bruised and expecting much harder punches before the calm, companies ride the COVID-19 storm

According to SmartTRAK Financial Dashboard, Q120 revenue for the US Joint Fluid Replacement market was down -2.8%, which is within the range predicted by market leaders and physicians in SmartTRAK’s Impact of COVID-19 on the US Joint Fluid Replacement and Regenerative Medicine Injectable Markets for Knee OA*. Albeit revenue is down for Q120, the stay-at-home orders across US states triggered by the rapid spread of COVID-19 were not implemented until mid-March, which helped to mitigate what could have been much bigger losses. 

Among the many topics covered in the comprehensive Q120 US Joint Fluid Replacement Market Recap* are:

Continue Reading
3 min read

Weathering the COVID-19 Storm in Orthobiologics: An Interview with Steven Sampson, DO

By Freddy Buntoum on 5/11/20 9:00 PM

The COVID-19 pandemic is having a significant effect on physician practices in Orthopedics and Sports Medicine, including the number of elective procedures being postponed, when normal operations might resume, the adoption of telemedicine, delivery of physician education and interactions with industry. To find out more, SmartTRAK Analyst Freddy Buntoum interviewed Steven Sampson, DO, founder of The Orthobiologic Institute (TOBI) and an internationally-recognized expert in the field of non-surgical orthopedics and the science of sports medicine. To hear Dr. Sampson’s take on how things might evolve throughout the rest of 2020, and how his practice and organization are supporting patients and other stakeholders, click on the following video to listen to the interview recorded via Uberconference (25:20 minutes). A transcript of the interview can be downloaded below.

Continue Reading
3 min read

Q419/FY19 Soft Tissue Fixation Market Recap: Overall Positive Growth

By Freddy Buntoum on 4/29/20 9:21 AM

For the fourth quarter of 2019, WW Soft Tissue Fixation Market revenue was up +3.7% YoY. Aggregate growth for the quarter especially benefited from healthy and continued revenue gains in the Hip Labral repair segment, which was up +8.9% YoY. And, to a smaller extent, the Meniscal repair and the Shoulder repair segments also contributing to the overall WW market growth in Q419 with YoY increases of 4.4% and 4.1%, respectively, based on SmartTRAK Financial Dashboard. Similar to other orthopedic markets, such as the Joint replacement market, Soft Tissue Fixation is typically seasonal with lower sales during Q3 and recovery in Q4 driven by a year-end increase in the number of elective procedures and stronger product push as competitors race to finish the year at or above their respective budget projections.

Continue Reading
9 min read

Swim with the Sharks: A Deep Dive in the Biologic Association Think Tank

By Freddy Buntoum on 4/17/20 2:23 PM

The Biologic Association kicked off its very 1st Summit (Feb 5-7, 2020 in Carlsbad, CA) with what turned out to be a big crowd-pleaser. Initially set up as a “by invitation only” attendance, the Summit’s opening program, “Biologic Association Think Tank” raised such a high level of interest that everyone in attendance was ultimately let into the session.

The format for the Think Tank was quite similar to the hugely popular television show “Shark Tank.” Only in this session, the “school of fish” (contestants/presenters) included a lineup of industry and/or academic researchers in the field of Orthobiologics who gave presentations on their respective lead product candidates.

Continue Reading

    Recent Articles